Key findings from the QWINT-1 trial reveal:
- Efsitora is as effective as glargine for HbA1c reduction.
- Efsitora has lower rates of severe hypoglycemia.
- Insulin doses required were less with efsitora.
- A significant percentage of patients achieved HbA1c below 7%.
- Serious adverse events were comparable between groups.
- Average weight gain was slightly higher in the efsitora group.
